Clinical Trial

A Phase Ib Study of HS-10504 Combined Therapy in NSCLC

Name: A Phase Ib Study of HS-10504 Combined Therapy in NSCLC — clinical trial record (NCT07414953)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This is a multi-center, open-label, phase I study to evaluate the safety, efficacy, pharmacokinetics (PK), and immunogenicity of HS-10504 combined therapy in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).

Trial Details

NCT Number	NCT07414953
Lead Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions	Lung Cancer
Enrollment	400 participants
Start Date	2026-03-30
Primary Completion	2027-04-30 (estimated)
Study Completion	2028-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-17